Portal de Periódicos da CAPES

Coenzyme Q_10 and Congestive Heart Failure

2000; American College of Physicians; Volume: 133; Issue: 9 Linguagem: Inglês

10.7326/0003-4819-133-9-200011070-00021

1539-3704

Stephen S. Gottlieb,

Advanced battery technologies research

Letters7 November 2000Coenzyme Q10 and Congestive Heart FailureStephen S. Gottlieb, MD, Meenakshi Khatta, MS, CRNP, and Michael L. Fisher, MDStephen S. Gottlieb, MDUniversity of Maryland; Baltimore, MD 21201 (Gottlieb, Khatta, Fisher)Search for more papers by this author, Meenakshi Khatta, MS, CRNPUniversity of Maryland; Baltimore, MD 21201 (Gottlieb, Khatta, Fisher)Search for more papers by this author, and Michael L. Fisher, MDUniversity of Maryland; Baltimore, MD 21201 (Gottlieb, Khatta, Fisher)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-9-200011070-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:The use of coenzyme Q10 in congestive heart failure continues to be advocated on the basis of anecdotal information and uncontrolled data. Dr. Sinatra's letter uses unsubstantiated theoretical concerns to ignore and discount the implications of a negative controlled trial. It is possible that higher concentrations of a substance might be more beneficial than lower concentrations. Nevertheless, in patients with heart failure, most drugs that are useful at high doses are also effective at lower doses. To use Dr. Sinatra's example, patients receiving angiotensin-converting enzyme inhibitors have fewer hospitalizations when the drug is given at a high dose, ...References1. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al . Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-8. CrossrefMedlineGoogle Scholar2. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al . Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807-16. CrossrefMedlineGoogle Scholar3. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr. 1988;66:583-90. CrossrefMedlineGoogle Scholar4. . Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Maryland; Baltimore, MD 21201 (Gottlieb, Khatta, Fisher) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Effect of Coenzyme Q10 in Patients with Congestive Heart Failure Meenakshi Khatta , Barbara S. Alexander , Cathy M. Krichten , Michael L. Fisher , Ronald Freudenberger , Shawn W. Robinson , and Stephen S. Gottlieb Coenzyme Q10 and Congestive Heart Failure Stephen T. Sinatra Metrics Cited ByStatins in heart failure. Beyond the lipid lowering effectEndothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure 7 November 2000Volume 133, Issue 9Page: 745-746KeywordsAngiotensin converting enzyme inhibitorAttentionBloodCoenzymesDrugsHeart failureHospitalizationsLongitudinal studiesMorbidityMortality ePublished: 7 November 2000 Issue Published: 7 November 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...